What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

EXPLORE

Society & Culture

Health & Fitness

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/40/32/49/4032499b-f2e3-292b-15ed-d1fac5de81c0/mza_2452564919629067865.jpeg/600x600bb.jpg

GvHD Hub

Scientific Education Support

18 episodes

17 hours ago

The GvHD Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in GvHD. Our aim is to enhance knowledge in GvHD, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Show more...

All content for GvHD Hub is the property of Scientific Education Support and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

The GvHD Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in GvHD. Our aim is to enhance knowledge in GvHD, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Show more...

https://assets.pippa.io/shows/5ef0ad954320b108b12f7e8d/1592831402822-6b3616a700fc4c91f71700e754cfa7cd.jpeg

What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

GvHD Hub

13 minutes 57 seconds

3 years ago

What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to steering committee member Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

In this podcast, Mohty highlights the latest advances in the field of steroid-refractory acute GvHD and emphasizes the importance of prevention, commenting on anti-thymocyte globulin (ATG), allogeneic hematopoietic stem cell transplant (allo-HSCT), and posttransplant cyclophosphamide. Mohty also mentions the HERACLES trial (NCT03225937) and the use of the JAK inhibitor ruxolitinib.

Hosted on Acast. See acast.com/privacy for more information.